Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of thromboinflammatory diseases.
The Unmet Need
Cardiovascular diseases carry significant morbidity and mortality. They are in general driven by overactive coagulation at the sites of vascular injury, caused by disease processes, such as atherosclerosis and vascular inflammation. The currently available therapies only partially address these clinical problems.
Our Story
Aplagon is based on pioneering research on mast cell-derived heparin proteoglycans (HEP-PG) performed by Prof. Riitta Lassila’s group at Wihuri Research Institute in Helsinki, Finland. These early discoveries led to Aplagon’s APAC, a heparin proteoglycan mimetic. After years of building a robust body of scientific evidence, APAC is now in clinical studies in two lead cardiovascular indications.
Location
Aplagon has its offices and laboratory at Biomedicum Helsinki, the most prominent life science hub in Finland.
IP
Aplagon has strong IP protection for APAC and its underlying technology.
Investors
Aplagon is backed by leading Finnish investors.
